Journal of Medicinal Chemistry · 1998 · 54 citations · 4 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyPsychopharmacologyDopaminergic PharmacologyDrug ReceptorsDrug-receptor InteractionsLigand BindingReceptor PharmacologySerotonergic Pharmacology5-Hydroxytryptamine Receptor PharmacologyDopamine D2-like ReceptorsLigand Binding SelectivityMethyl Group ReplacementPharmacology Of Serotonergic AgentsSelectivitySerotonin Receptor BindingSerotonin Receptor Pharmacology
Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Although spiperone also binds at 5-HT2C receptors, it is one of the very few agents that display some (ca. 1000-fold) binding selectivity for 5-HT2A versus 5-HT2C receptors and, hence, might serve as a useful template for the development of novel 5-HT2A antagonists if the impact of its various substituent groups on binding was known. In the present investigation we focused on the 1, 3,8-triazaspiro[4.5]decanone portion of spiperone and found that replacement of the N1-phenyl group with a methyl group only slightly decreased affinity for cloned rat 5-HT2A receptors. However, N1-methyl derivatives displayed significantly reduced affinity for 5-HT1A, 5-HT2C, and dopamine D2 receptors. Several representative examples were shown to behave as 5-HT2 antagonists. As such, N1-alkyl analogues of spiperone may afford entry into a novel series of 5-HT2A-selective antagonists.
4
Psychopharmacology: The Fourth Generation of Progress
James J. Brophy · JAMA · 1995 · 1.6K citations
Abd M. Ismaiel, Joseph De Los Angeles, Milt Teitler et al. · Journal of Medicinal Chemistry · 1993 · 54 citations · Full text